fbpx

KCI Announces Significant Advancement in Negative Pressure Wound Therapy Drape Technology

Introducing DERMATAC Drape, the First-Ever
FDA Cleared Silicone-Acrylic Hybrid NPWT Drape

SAN ANTONIO–(BUSINESS WIRE)–KCI, an Acelity Company, today announced that the Company has received
510(k) clearance from the U.S. Food and Drug Administration (FDA) for
DERMATAC™ Drape, a proprietary silicone-acrylic hybrid drape that
provides both clinical and operational benefits, as an accessory to
certain of KCI’s Negative Pressure Wound Therapy (NPWT) Systems.
Constructed with a precise combination of silicone and acrylic,
DERMATAC™ Drape conforms to different anatomical locations, adapting to
the body and providing a tight, highly-effective seal for 48 to 72
hours, including uneven areas, for wound protection, creating the ideal
balance for wound healing support.

“We were able to re-engineer what was possible in design and chemistry
to bring to life this new drape,” said R. Andrew Eckert, Chief Executive
Officer, KCI. “The result is a remarkably effective therapeutic tool
that is friendly to the skin and ensures a tight seal to protect wounds
on all anatomical locations. It offers enhanced functionality relative
to other drapes currently available, benefitting patients and healthcare
providers alike.”

DERMATAC™ Drape offers healthcare providers the ability to place and
reposition the drape during the initial dressing application, ensuring
proper wound sealing and effectively overcoming challenges relative to
traditional polyurethane drapes commonly used with NPWT by reducing
product waste, minimizing risk to the peri-wound area and improving
patient satisfaction due to little skin irritation and pain.
Additionally, DERMATAC™ Drape could result in less training for
clinicians due to ease of application, while also providing faster
dressing changes compared to standard of care.

“The pressure of NPWT placements can be immense, and the process
cumbersome and time-consuming for clinicians caring for very ill
patients who often deal with excruciating pain during these periods,
especially those with large and severe wounds,” said Ralph J.
Napolitano, Jr., DPM, CWSP, FACFAS, OrthoNeuro, Columbus, Ohio. “The
combination of benefits in DERMATAC™ Drape provides the necessary seal
and protection with a near pain-free experience for the patient;
moreover, the ability to easily reposition DERMATAC saves the clinician
significant time and reduces the amount of wasted drape. I’ve found that
it certainly reduces anxiety for providers as dressing changes comprise
the most time-consuming element in caring for wounds.”

“As the industry leader, we see a tremendous opportunity to advance the
technology behind drapes and dressings for NPWT,” added Eckert. “If we
provide clinicians with more options, then we expect that more people
will have the opportunity to receive this differentiated therapy. By
fulfilling our promise to deliver new technology to market, we can help
physicians intervene sooner, ease the burden of therapy, and improve how
patients heal all while reducing costs.”

KCI designed DERMATAC™ Drape to evolve the current standard of
care with improved patient benefits in mind; however, additional
operational advantages include the ability to reposition the drape
during dressing changes that may result in a reduction of healthcare
professional’s time and skill-level required to manage workflow of wound
patients.

“In the home care setting, DERMATAC™ Drape holds promise for those
patients receiving care for their chronic wounds as they struggle to
maintain normalcy in their daily lives,” added Dr. Napolitano. “The
combination of silicone and acrylic and three-day wear time allows for
patients to shower and ambulate while their wound remains protected and
sealed, even in anatomically challenging areas. In addition, the
skin-friendly benefits have the potential to have profound effects on
patient satisfaction during dressing changes.”

KCI currently offers DERMATAC™ Drape in a Limited Commercial Release
(LCR) in the US, and the early feedback from healthcare professionals
and patients is largely positive. DERMATAC™ Drape will be more widely
available to healthcare providers in the United States beginning in the
summer of 2019.

About DERMATAC™ Drape

DERMATAC™ Drape is a single-use, proprietary silicone-acrylic hybrid
drape that is used as an accessory to ACTIV.A.C.™, INFOV.A.C.™, V.A.C.
SIMPLICITY™, V.A.C.VIA™, V.A.C. FREEDOM™, V.A.C.ULTA™ and V.A.C.RX4™
Negative Pressure Wound Therapy Systems. Constructed with a precise
combination of silicone and acrylic, DERMATAC™ Drape conforms to
different anatomical locations, adapting to the body and providing a
tight, highly-effective seal for 48 to 72 hours, including uneven areas,
for wound protection, creating the ideal balance for wound healing
support.

About KCI, an Acelity Company

KCI, an Acelity Company, is a well trusted brand in advanced wound care.
We are a leader in negative pressure wound therapy, providing solutions
for both wound healing and surgical management. Our product offerings
are available in more than 90 countries and deliver value through
solutions that speed healing. KCI is a leader in quality, safety and
customer experience and is committed to advancing the science of
healing. Headquartered in San Antonio, Texas, KCI employs approximately
4,500 people worldwide.

Contacts

Kathryn Skeen
Corporate Communications
Phone:
+1-210-882-2067

Email: [email protected]

Jathan Tucker
Investor Relations
Phone:
+1-210-255-6816

Email: [email protected]

leverton

Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.

You May Also Like